IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Nanoscale Systems: A Promising Advancement in Microbial Pharmaceutics

[1]Jiya Bhanushali*, [2]Mihir Mishra, [3]Ashish Prajapati, [4]Prachi Jangam, [5]Pallavi Singh

[1]Student at Smt. B.N.B Swaminarayan Pharmacy College, [2]Student at Smt. B.N.B Swaminarayan Pharmacy College, [3]Student at Smt. B.N.B Swaminarayan Pharmacy College, [4]Student at Smt. B.N.B Swaminarayan Pharmacy College, [5]Student at Smt. B.N.B Swaminarayan Pharmacy College

[1]B.Pharm

[1]Smt. B.N.B Swaminarayan Pharmacy College, Salvav, Vapi, India

***Abstract*:-** An increasing worldwide problem is antimicrobial resistance, which makes conventional antimicrobials less effective and calls for creative alternatives. As a potential substitute, nanoparticles are propelling the creation of innovative antibacterial medications using drug delivery methods based on nanotechnology. Advanced techniques for identifying and treating a range of illnesses are made possible by their use in nanomedicine and nanomaterials. To efficiently treat bacterial infections, a number of advanced drug delivery techniques have been developed, such as pH-sensitive nanoparticles, surface charge-modifying nanocarriers, microencapsulation, and microbially triggered release. These developments decrease the development of resistance, increase the dispersion of targeted drugs, and extend therapeutic effectiveness. Additionally, nanotechnology opens up new avenues for study by facilitating the development of novel antibacterial mechanisms. Nanoparticles are preferable to traditional antimicrobial treatments because of their distinct physicochemical characteristics, which include greater surface area, functionalizable structures, and improved reactivity. They save treatment costs, lessen toxicity, and lessen antibiotic resistance. They also enhance antimicrobial medications' pharmacokinetics and therapeutic effects, guaranteeing increased bioavailability and long-lasting effects. Beyond the treatment of infections, nanotechnology enables quick, accurate, and economical therapeutic and diagnostic options. As nanoantimicrobial agents, nanoparticles eliminate pathogens by breaking down bacterial cell walls, blocking enzymes, and interfering with DNA replication. They are an affordable substitute for conventional antibiotics because of their excellent stability, which enables them to withstand harsh environments. A revolutionary development in microbial pharmaceutics is the incorporation of medication delivery using nanoparticles. Because of their adaptability and wide range of applications, nanoparticles are revolutionizing current medicine by providing next-generation antimicrobial treatments that are more powerful, long-lasting, and immune to changing microbial threats.

Keywords:- Dendrimers, Drug delivery system, Gastric infection, Gastrointestinal tract, Multidrug resistance, Nanoparticle.

1 Introduction

Drug delivery methods based on nanotechnology are efficient means of getting beyond the pharmacokinetic restrictions that come with traditional drug administration(1). Numerous nanoparticles have shown great therapeutic promise in the transport of antimicrobial drugs, including liposomes, carbon nanotubes, silica nanoparticles, and nano complexes. An developing technique that is essential to antimicrobial treatment for a wide range of illnesses is the use of nanoparticles in medication delivery. Metals and compounds with biological origins make up the majority of these antimicrobial nanoparticles(2). Targeted bacterial membrane disruption, better drug transport, higher drug functioning, and selective accumulation at infection sites owing to increased vascular permeability have all been achieved with surprising success in recent research. However, nothing is known about the precise method by which different bacteria are inhibited by nanoparticles. Their electrostatic charge-based interactions with microbial cell membranes lead to membrane rupture and integrity loss. Furthermore, oxidative stress brought on by the production of free radicals is primarily responsible for the toxicity of nanoparticles(3). The use of polymeric nanoparticles with surface charge changes for microbial cell wall-targeted delivery, antimicrobial targeting, and fighting antimicrobial resistance have all been the subject of substantial study in recent years(4). Along with other cutting-edge strategies like microbial nanoparticle manufacturing, silver nanoparticles have shown promise as a remedy for multidrug resistance. The composition, surface changes, inherent characteristics, and microbiological species of nanoparticles all influence their toxicity mechanism. Strong relationships between several elements of their antibacterial activity support their potential efficacy. Drug distribution is significantly hampered by biological barriers(5). For formulation scientists, problems including nonspecific medication dispersion and insufficient accumulation still present challenges. Nevertheless, delivery systems based on nanoparticles have shown themselves to be effective carriers that lessen the pharmacokinetic limitations of conventional drug delivery techniques. They provide the best way to get beyond microbial barriers and guarantee that treatment chemicals are delivered to diseased locations precisely(6).



Figure 1 Various nanoparticulate drug delivery systems to treat infections or drug resistance caused by different pathogenic microorganisms.

Antimicrobial infections and multidrug-resistant organisms may be effectively treated using a variety of antimicrobial nanoparticles and nano-sized carriers(7). The preferred antibacterial agents in contemporary medicine are nanoparticles because of their distinct physicochemical characteristics and high surface area-to-volume ratio. In many therapeutic uses, such as wound dressings based on nanoparticles, gels, lotions, and medical equipment coated with nanoparticles, nanoparticles themselves function as potent antibacterial agents. Numerous nanoparticles have been investigated as antimicrobial medicine carriers that shield pharmaceuticals from disease resistance mechanisms(8). To improve antibacterial activity and fight multidrug resistance, these nanoparticles provide both independent and complementary approaches. Extensive research on their toxicity and clinical uses as drug transporters and antimicrobials is still lacking, nevertheless. Over the last several decades, significant scientific progress has been achieved in creating nano-sized vesicles with unique physical and biological characteristics for drug delivery applications. Dendrimers, polymeric nanoparticles, lipid-based nanoparticles, virus-based nanoparticles, and liposomes are a few examples(9). Nanoparticles have the potential to enhance the therapeutic index of currently available medications by reducing toxicity, boosting effectiveness, and guaranteeing sustained steady-state drug release, as shown in Figure 1. They also improve the solubility and stability of drugs, which helps create novel chemical entities that may have therapeutic uses. Targeting ligand conjugation is made possible by the adaptability of nanoparticle surface chemistry, guaranteeing accurate drug delivery. However, there are still a number of obstacles to overcome before using medication delivery based on nanomedicine to combat multidrug resistance(10). Currently, drug-loaded nanoparticles have the ability to spread across healthy tissues, which calls for further study to maximize their therapeutic uses while reducing side effects.

2 History

Antimicrobial drug resistance, often known as multidrug resistance (MDR), has presented the biopharmaceutical sector with serious difficulties during the last several decades(11). A rising problem that is gradually spreading around the globe is the rise of microbial resistance to a variety of authorized treatment medicines. This state is exploited by opportunistic and pathogenic bacteria, which flourish in conditions where conventional medications are unable to stop their development(12). Increased death rates, a greater prevalence of illness among patients, and a significant increase in the expense of lengthy therapies are all direct effects of MDR. The overuse and often needless prescribing of antibiotics is one of the main causes of this problem. MDR has become a serious worldwide health emergency as a result of the uncontrolled and careless use of these drugs(13). Because antimicrobials are ineffectual against resistant microorganisms, infectious illnesses continue to take countless lives each year. Reduced bioavailability is also caused by a number of biological and environmental variables, as well as the instability and low solubility of many medicinal chemicals. Therefore, the creation of sophisticated medication delivery systems that can overcome these constraints is desperately needed. Effective targeting is hampered by the structural complexity of malignant tumors(14). But it also gives researchers a chance to investigate medication delivery methods based on nanotechnology. Although the extensive use of antibiotics by people is a primary factor in the development of resistance, agricultural practices also have a significant influence. The issue is made worse by the widespread use of antimicrobial compounds in plants as insecticides and growth promoters. The problem has now gotten to the point where there are no longer enough effective treatment options to handle the growing number of microbiological diseases(15). To successfully combat MDR, this situation calls for swift response and the use of innovative medication delivery techniques. A number of strategies can be taken to address this problem, including (a) educating medical and paramedical professionals about the responsible use of antibiotics; (b) reducing the use of antibiotic agents whenever feasible; and (c) creating novel drug delivery systems to get past MDR. The third strategy is a prospective technology innovation that may directly solve the MDR dilemma, while the previous two options rely heavily on government regulations and public awareness(16). To sustain the advantages of antimicrobial agents and an enhanced standard of living in this age of antimicrobial resistance, it is essential to recognize and address this worldwide challenge. However, the lengthy and intricate regulatory clearance procedure for new antimicrobial medications delays their incorporation into standard medical care(17). Since research over the past 20 years has shown how challenging it is to create broad-spectrum antimicrobials that are both safe and effective for usage, the scientific community still faces challenges in the identification and categorization of novel antimicrobial agents. Almost every microbial infectious agent, such as viruses, bacteria, fungi, and parasites, has some degree of resistance, which raises death rates(18). Known as "superbugs," these very resilient types represent a serious threat to public health. Recent years have seen a sharp decline in the effectiveness of antibiotics in treating common illnesses, bringing us closer to a day when even small bacterial infections may no longer be treated. The use of antibiotics has been steadily increasing in both developed and developing countries, especially in hospital and community healthcare settings(19). Microorganisms develop resistance due to genetic mutations, which are exacerbated by selection pressure from overuse of antibiotics, giving mutant strains a survival advantage. Unsafe food handling procedures, insufficient infection control measures, inappropriate antibiotic usage, and poor sanitation all contribute to the spontaneous regeneration of resistant strains(20). Understanding the underlying issues and the pressing need to avoid microbial resistance are crucial given the increasing effect of MDR. One of the most important steps in overcoming these obstacles is the creation of innovative medication delivery systems(21). In order to transform the treatment of

MDR-related illnesses and guarantee successful therapeutic results in the future, it will be essential to comprehend nanoscale drug delivery processes, as shown in Figure 2(22).



Figure 2 Nanoscale for the understanding of nanoparticulate drug delivery size.

3 Nanoparticles (NPS) advantages over conventional drug delivery systems

The promise of nanoparticles in targeted medication delivery, improving bioavailability, lowering drug toxicity, and lessening negative effects on essential organs has been acknowledged(23). For both hydrophilic and hydrophobic medications, nanoparticle-based drug delivery systems now provide an affordable and useful option that supports a variety of administration routes, such as parenteral, intraocular, intranasal, and oral. Nanoparticle-based systems provide a number of noteworthy benefits over traditional drug delivery techniques, which are listed below:

- To guarantee targeted medication delivery to certain cells or tissues while permitting regulated release throughout the body, nanoparticles might encapsulate, conjugate, or combine different therapeutic substances(24).
- These nanocarriers provide accurate and efficient therapy by delivering medications to tiny and difficult-to-reach locations.
- Utilizing a variety of biomaterials and polymers, recently developed nanoparticle-based drug delivery methods optimize physical qualities while providing more control over drug release.
- Complex biological molecules can be transported more easily thanks to nano-based medicine delivery, even to difficult-to-reach places like the blood-brain barrier. Nanoparticles improve bioavailability, guarantee regulated drug release, and provide precisely focused treatment by increasing the aqueous solubility of weakly water-soluble medications.
- Multidrug resistance (MDR) brought on by several physiological barriers is successfully overcome by the nanoparticulate drug delivery technology.
- Nanoparticle-based medication delivery makes it possible to quickly identify and measure tumor cells, which enhances cancer diagnosis.
- It is simple to alter the size and surface properties of medication particles to allow for both active and passive drug targeting during parenteral delivery(25).
- Targeting ligands functionalize the surfaces of nanoparticles to guarantee site-specific drug delivery for improved therapeutic precision.
- By focusing medication distribution on the targeted location and reducing exposure to healthy tissues, nanoparticulate drug delivery lowers systemic drug toxicity.
- When administering biologics—such as proteins, peptides, and nucleic acids—surface-modified drug carriers aid in avoiding immunological reactions.
- Because of the controlled particle size, nano-based drug delivery ensures targeted dispersion and may efficiently provide controlled and sustained drug release.
- A broad range of illnesses and ailments, including cancer cell biomarkers, may be quickly detected thanks to the widespread usage of nanoparticles in diagnostic applications.
- The limits of traditional imaging methods have been successfully overcome by using fluorescent nanoparticles to increase the accuracy of medical imaging. Additionally, nanotechnology is essential to the creation of sophisticated in vivo diagnostic equipment including improved endoscopic instruments and ingestible imaging capsules(26).

Because nanoparticulate drug delivery allows for precise medication targeting without needless bodily invasions, it plays a crucial role in disease diagnosis. Because of their large surface area and distinct physicochemical characteristics, metallic nanoparticles—such as those made of gold, silver, and metal oxides like zinc and iron—have shown enormous promise for use in biological applications(27).

4 Disadvantages of nanoparticles (NPS)

It's crucial to take into account any possible negative effects of nanotechnology while talking about its benefits. Preventing failures in future medication formulations requires an understanding of the limits of nanoparticulate drug delivery(28). Drug delivery systems based on nanotechnology are expensive and complicated to design and produce, thus it's important to recognize these difficulties rather than ignore them. As shown below, the drawbacks of nanoparticles differ according on their composition method, mode of administration, and other pertinent variables:

- The medicinal content of nanoparticles is significantly lost during application when they are applied topically. The effectiveness of this approach is further diminished by the absence of a strong mechanism for regulated medication release.
- Drug degradation, polymorphic transitions, particle growth, instability in formulations with high water content, and a restricted ability to load hydrophilic medicines are some of the issues that arise with long-term storage of nanoparticles, which makes administration less comfortable(29).
- Nanoparticles tend to agglomerate because of their huge surface area and tiny particle size, which may cause problems including decreased antibacterial efficacy, trouble managing both dry and liquid formulations, and restricted drug-loading capacity.
- The reticuloendothelial system may recognize and eliminate nanoparticles when they are given parenterally, which might affect medication bioavailability and lessen therapeutic efficacy.

As was previously said, there are several important advantages of nanotechnology. It is still commonly used in medication delivery in spite of these disadvantages since many of them may be overcome with creative solutions(30). To further increase the efficacy of nanoparticulate drug delivery systems, several developments in nanotechnology have been developed to reduce particle aggregation and address storage-related problems.

5 Applications of nanoparticles (NPS) in microbial pharmaceutics

Nanoparticles have several real-world uses in the microbiological and medicinal domains in addition to traditional drug delivery techniques, opening up a plethora of options in these domains. In contemporary biomedicine, nanotechnology is essential, especially for medication delivery(31). By encasing medications, improving cell membrane permeability, and guaranteeing an ideal therapeutic drug level inside the body, nanoparticles not only increase drug solubility but also dramatically increase bioavailability(32). Novel targeted medication delivery devices have been created as this subject grows and our understanding of nanotechnology and transdisciplinary techniques develops. Many poorly soluble, impermeable, and very toxic medications may now advance into clinical trials as possible therapeutic agents because to these technologies, which allow the exact delivery of certain medications to their designated regions of action(33). The uses of nanoparticles in microbial pharmaceutics are now being investigated extensively. A brief synopsis of these applications will be given in this section.

5.1 Nanoparticles (NPS) against pathogens

Regardless of the pathogen or medicine type, pharmaceuticals are often more effective when administered by nanoparticles. The antibacterial activity of a variety of medications is improved by both metallic and non-metallic (organic) nanoparticles. The intracellular drug concentration may be increased by up to 10 times using targeted nanoparticles(34). Drugs, with or without ligand attachment, may therefore efficiently enter cellular organelles or diseased tissues. Leishmaniasis, viral disorders, deep-seated skin infections, and brain infections are among the difficult infections that may be successfully treated using nanoparticles. Reduced toxicity and fewer adverse effects result from less drug buildup in non-targeted parts of the body. When paired with nanoparticles, many antimicrobial medicines have effectively reduced nephrotoxicity and hematological problems(35). Nanoparticle-based administration not only increases therapeutic efficacy but also provides more palatable treatment plans for patients. Using nanoparticles such solid lipid nanoparticles, polymeric micelles, polymeric nanoparticles, and liposomes may lower the necessary therapeutic dose and prolong dosing intervals to 1–10 days. Increased residence time or a longer half-life might be the cause of these protracted gaps(36). Furthermore, extended medication retention is further facilitated by the mucoadhesive qualities of nanoparticles. Nanoparticles greatly increase the half-life and therapeutic efficacy of the loaded medicines by halting drug breakdown.

5.2 Synergistic effect of nanoparticle (NP) with antimicrobials

The emergence of multidrug resistance (MDR), which is now a significant problem, has made the conventional chemotherapy strategy of using tiny antibiotic molecules to treat infections less and less effective. Patients now have fewer alternatives for treating MDR bacteria since last-line antibiotics are being employed more often to fight resistant microorganisms while the efficacy of first-line antimicrobial medicines continues to deteriorate(37). One of the last methods left for combating pathogenic germs is the prudent use of last-line antibiotics. One possible strategy to combat microbial resistance is to incorporate antibiotic compounds into nanoparticles, especially metallic nanoparticles like silver and gold. This strategy increases effectiveness by using the complementary effects of conjugated antibacterial medications and nanoparticles. According to studies, the antibacterial activity of silver nanoparticles has been enhanced when combined with widely used medicines that target gram-positive bacteria, such as erythromycin, amoxicillin, and vancomycin(38). Though the results varies depending on the medication and the kind of nanoparticle utilized, studies have also shown that conjugating tiny antibiotic medicines with nanoparticles does not always result in improved antimicrobial properties. Notwithstanding these differences, a number of investigations and observations indicate that this strategy has a great deal of promise to increase the efficacy of traditional antimicrobial therapies(39).

5.3 Nanoparticles (NPS) against MDR

A number of illnesses, including bacterial, fungal, and viral diseases including HIV and candidiasis, are causing a growing amount of resistance to antimicrobial medicines(40). Enhancing therapeutic effectiveness by avoiding several resistance mechanisms, including efflux pumps, thick cell walls, and enzymatic degradation, is the main function of nanoparticulate drug delivery in treating multidrug resistance (MDR). Studies have shown that delivering medications in conjunction with nanoparticles not only increases pharmacological efficacy but also reduces the risk of resistance emerging following treatment(41). Dense bacterial populations known as microbial biofilms adhere to both biotic and inert surfaces. One of the main virulence factors for many bacteria that cause infections is the production of biofilms. Because of their extensive microbial molecular and genetic relationships, which sometimes include numerous species, as well as their complex biological and physical properties, these biofilm-associated illnesses are difficult to treat with single-target therapies or conventional antibiotic medications(42). Microbes that produce biofilms quickly produce an extracellular polymeric matrix that serves as a barrier, enhancing the MDR effect and making it harder for medications to pass through. Furthermore, biofilms often develop in difficult-to-reach places, making current therapies ineffectual(43). At the moment, they are in charge of most chronic microbial infections, and in extreme situations, removing the contaminated tissue or implant from the body is the best course of action. It has been shown that certain drug-loaded nanoparticles may break through bacterial walls and destroy biofilms(44). Targeted or combination therapy are necessary because the complicated environment of biofilm development and the medication tolerance that goes along with it provide serious problems for conventional antibacterial treatments. When opposed to therapies that use nanoparticle-based drug delivery, the formation of resistance after treatment with free medicines is far more prevalent since the nanoparticulate system offers a multifunctional approach to treating bacteria(45).

5.4 Nanoparticles (NPS) as anti-infective agents

Antibiotics are often more effective against vulnerable bacteria when coupled with antimicrobial nanoparticles than when used alone(46). Uncoated antimicrobial nanoparticles, on the other hand, often show comparable or even higher effectiveness than both the drug-nanoparticle combination and the free drug when dealing with resistant bacteria. Therefore, it has been shown that combined medication therapy using antibiotics and nanoparticles improves the effectiveness of treatment against resistant microorganisms(47). Bare nanoparticles may also successfully stop the development of new bacterial strains, eradicate bacterial colonies, and hinder the formation of biofilms. Certain nanoparticles, especially metallic ones, have been studied for their antibacterial qualities against very resistant bacterial strains in both lab and real-world situations(48). Among them, gold nanoparticles, as well as other metallic nanoparticles like copper and silver, are the subject of much research. Strong antimicrobial qualities, such as antifungal, antiviral, anti-inflammatory, and antibacterial activity, have been shown by silver nanoparticles in particular. For millennia, silver has been used for therapeutic reasons. Silver nanoparticles have a higher toxicity to microbes than other metallic nanoparticles, yet they are less harmful to human cells(49). Their most promising uses, including as biosensors and wound healing therapies, have been noted in the pharmaceutical industry(50). In particular, silver nanoparticles are combined to create antibacterial gels that are used topically to treat burns. Because they overcome the drawbacks of conventional ointments and provide improved effectiveness via nanoparticulate drug delivery methods, these gels are also often used to treat a variety of skin illnesses(51).

5.5 Nanoparticles (NPS) for gastric infection

One of the most common and dangerous illnesses that affect the gastrointestinal (GI) tract is gastric infection(52). Making sure the medicine effectively passes through the GI surface and reaches the bacterial flora causing the illness is a significant problem in traditional drug administration. Eliminating Helicobacter pylori is essential to avoiding serious difficulties since it was discovered to be a carcinogenic agent towards the end of the 19th century(53). Adhering to the mucin layer, mucoadhesive nanoparticles efficiently enter the cellular junctions that are home to pathogenic microorganisms. Consequently, the nanoparticulate technology ensures the total removal of microbial biofilm by extending drug retention in the GI tract and permitting continuous drug release over a prolonged period of time(54). Furthermore, customized ligand nanoparticles are made especially to target certain bacterial strains, reducing needless GI tract irritation. A frequently used medication may be used to efficiently remove both the spiral and coccoid types of H. pylori by nanoparticulate drug delivery(55). Proton pump inhibitors and antibacterial medicines are two examples of the many medications that are now utilized in combination to improve overall treatment effectiveness and optimize dose regimens(56).

5.6 Nanoparticle (NP) as vaccine

It is crucial to create efficient plans for both avoiding and treating different infectious illnesses. One of the best medical innovations for both preventing and treating illnesses is still vaccination(57). Purified proteins, peptides, or recombinant forms of the target pathogen are often found in modern vaccines, which are intended to resemble the immune response. These vaccinations, however, often have minimal immunogenicity and little long-term efficacy(58). Nanoparticles have the potential to greatly improve this immune response. Drug delivery is significantly impacted by nanotechnology, especially in the area of immunization(59). Delivery techniques based on nanoparticles effectively bind adjuvants and antigens, enhancing the immune response(60). Furthermore, the adjuvant effect is naturally enhanced by several materials utilized in the manufacture of nanocarriers. Because it may elicit both systemic and mucosal immune responses, oral delivery is one of the most popular immunization techniques. As an organ with a lot of mucosa, the gut has a lot of immune cells(61). Oral vaccinations, however, have drawbacks such fast metabolism and gastrointestinal tract deterioration, need many doses to be effective. By encasing oral vaccinations in nanoparticles, this problem may be resolved(62). Transdermal delivery is another excellent immunization technique. Numerous immunocompetent cells that may elicit a robust immune response are found in the skin, the biggest organ in the human body(63). As a result, skin vaccinations are often more effective than other delivery methods. The size, content, and hydrophilic characteristics of nanoparticles all affect their capacity to penetrate(64). Notwithstanding their advantages, nanoparticles might have disadvantages that reduce overall effectiveness, such as early drug release before it reaches the target cells. Nanoparticles also serve as carriers for adjuvants, which are necessary to guarantee the vaccinations' sustained effectiveness(65). This strategy is often used in different vaccine formulations, enabling improved safety, a greater immune response, and longer-lasting protection. Additionally, nanoparticles shield antigens against deterioration, greatly boosting the efficacy of vaccines(66).

5.7 Nanoparticles (NPS) as theranostic

A novel strategy for lessening the adverse effects of chemotherapeutic medications has been presented with the inclusion of pharmaceuticals into nanoparticle carriers(67). Early illness detection, diagnosis, and treatment are the main objectives of "theranostic" approaches, which are a mix of therapeutic and diagnostic techniques(68). Even for illnesses that are life-threatening, this novel technique has a lot of potential. In a number of ways, theranostics combines therapeutic and diagnostic substances. One approach is encasing the drugs in nanoparticles for controlled release, while another combines therapeutic compounds with imaging-related nanoparticles(69). Many nanoparticles have been created to serve as both diagnostic instruments and carriers for the delivery of drugs and genes. When nanostructured medications are utilized, these nanosized materials provide a rare chance for the early discovery of deadly illnesses and allow for real-time monitoring of therapy effects(70). Certain nanoparticles are made to include both an imaging agent and an active medicinal component in one structure, making it easier to diagnose and treat illnesses. Additionally, there may be major benefits to encapsulating a therapeutic and diagnostic agent in a single theranostic nanoparticle(71). However, there may be health hazards linked to the unique physicochemical characteristics that make nanoparticles useful for both diagnosis and therapy. Although a number of theranostic systems are already used in microbial pharmaceutics, theranostic techniques based on nanoparticles are less often employed because of toxicity issues and a lack of thorough knowledge on their pharmacokinetics(72).

5.8 Nanoparticles (NPS) for pulmonary infections

Because of resistant bacterial strains in immunocompromised people, tuberculosis is increasingly occurring as a pulmonary illness. Every year, complications from cystic fibrosis are responsible for about 90% of fatalities(73). Formulation scientists are now concentrating on different kinds of nanoparticles to improve treatment effectiveness and provide a more practical administration method with adjusted dose intervals in order to solve this problem(74). Drug delivery methods based on nanoparticles have shown great promise in the treatment of respiratory tract infections. Staphylococcus aureus is one of the most prevalent bacterial infections that impact the pulmonary tract(75). Antibiotics and nanoparticles have been shown to work very well together to treat bacterial infections of the lungs. A variety of antibiotics may be efficiently transported by nanoparticles, allowing for targeted medication administration straight into affected lung tissue. Nanoporous particles exhibit better aerosolization than smaller, nonporous particles because of their larger diameter (more than 5 µm) and low density (around 0.4 g/cm³), which also prevents phagocytosis(76). In order to keep the medication in the intended pulmonary area and avoid exhalation, the aerodynamic characteristics of nanoparticles are essential. The respiratory system's contagious germs are the particular target of ligand-guided nanoparticles. However, the possibility of exhalation during delivery is a significant problem with inhaled medications(77). By forming nanoparticles into inhalable microaggregates, this problem has been lessened. When compared to traditional drug delivery systems, these aggregates have greater antibacterial effect because they stay in the lungs for a longer period of time(78). Nanoparticles also need to avoid being quickly cleared by the airways' mucociliary system. The use of mucoadhesive nanoparticles, such as formulations based on chitosan, which are functionalized to improve their adherence, is a viable strategy for extending their retention(79). When combined, these tactics let medicinal substances enter the lungs more deeply and deposit themselves there more heavily. However, a lot of experimental research has been done that primarily looks at the sustained-release characteristics and interactions of nanoparticles with biological systems, ignoring the existence of mucosal barriers(80).



Figure 3 Targeted nanoparticles in the treatment of the pulmonary tract infection.

6 Conclusion

Therapeutic uses of nanoparticles in the management of several infectious illnesses are very promising. A thorough analysis of the literature reveals that nanoparticles provide exciting new opportunities in microbial pharmaceutics. By focusing on certain infectious microbes, these nanoscale medication carriers improve the effectiveness of therapy. They are a useful weapon in the fight against illnesses that are difficult to treat since they also enhance medication performance, especially against germs that are resistant to many drugs. In addition to their antibacterial properties, nanoparticles help with a well-organized administration schedule, less side effects, enhanced absorption, and fewer doses. Researchers, physicians, and pharmaceutical scientists must work together across academic boundaries to produce nanoparticulate medication in microbial pharmaceutics. The drug's physicochemical qualities, drug-loading features, and the kind of illness being treated are some of the variables that influence the choice of nanoparticles. Furthermore, in the field of microbial pharmaceutics, nanoparticle-based drug delivery systems promise to guarantee accurate and efficient drug administration while also offering the possibility of developing more patient-friendly and efficient dosing schedules. The creation of innovative drug delivery methods is still a top priority in the field of microbial pharmaceutics, and nanoparticles are becoming one of the most popular methods. As a result, medication delivery via nanoparticles may be considered a revolutionary development in the industry, opening the door for further advancements in the management of microbial diseases.

References

1. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016 Oct;33(10):2373–87.

2. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol. 2009;4(7):411–4.

3. Gupta RB, Kompella UB. Nanoparticle technology for drug delivery. 2006 [cited 2025 Mar 21]; Available from: https://gimitec.com/file/49.pdf

4. Hamdallah SI, Zoqlam R, Erfle P, Blyth M, Alkilany AM, Dietzel A, et al. Microfluidics for pharmaceutical nanoparticle fabrication: The truth and the myth. Int J Pharm. 2020;584:119408.

5. Malik B, Pirzadah TB, Kumar M, Rehman RU. Biosynthesis of Nanoparticles and Their Application in Pharmaceutical Industry. In: Kalia VC, Saini AK, editors. Metabolic Engineering for Bioactive Compounds [Internet]. Singapore: Springer Singapore; 2017 [cited 2025 Mar 21]. p. 331–49. Available from: http://link.springer.com/10.1007/978-981-10-5511-9_16

6. Muthu MS, Feng SS. Pharmaceutical Stability Aspects of Nanomedicines. Nanomed. 2009 Dec;4(8):857–60.

7. Peltonen L. Practical guidelines for the characterization and quality control of pure drug nanoparticles and nano-cocrystals in the pharmaceutical industry. Adv Drug Deliv Rev. 2018;131:101–15.

8. Rai, Ph.D M, Shegokar, Ph.D R, editors. Metal Nanoparticles in Pharma [Internet]. Cham: Springer International Publishing; 2017 [cited 2025 Mar 21]. Available from: http://link.springer.com/10.1007/978-3-319-63790-7

9. Sheth P, Sandhu H, Singhal D, Malick W, Shah N, Serpil Kislalioglu M. Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production. Curr Drug Deliv. 2012 Apr 1;9(3):269–84.

10. Stark WJ, Stoessel PR, Wohlleben W, Hafner A. Industrial applications of nanoparticles. Chem Soc Rev. 2015;44(16):5793–805.

11. Acar J, Rostel B. Antimicrobial resistance: an overview. Rev Sci Tech-Off Int Epizoot. 2001;20(3):797–810.

12. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016;6(2):71–9.

13. Beyth N, Houri-Haddad Y, Domb A, Khan W, Hazan R. Alternative Antimicrobial Approach: Nano-Antimicrobial Materials. Evid Based Complement Alternat Med. 2015;2015:1–16.

14. Bibel DJ, Aly R, Shinefield HR. Antimicrobial activity of sphingosines. J Invest Dermatol. 1992;98(3):269–73.

15. Cowan MM. Plant Products as Antimicrobial Agents. Clin Microbiol Rev. 1999 Oct;12(4):564–82.

16. Cushnie TT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343–56.

17. Eliopoulos GM, Moellering RC. Antimicrobial combinations. Antibiot Lab Med. 1996;4:330–96.

18. Group WSW. Antimicrobial resistance. Bull World Health Organ. 1983;61(3):383.

19. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. Jama. 2016;316(11):1193–204.

20. Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin. 2020;30(4):619–35.

21. Rios JL, Recio MC. Medicinal plants and antimicrobial activity. J Ethnopharmacol. 2005;100(1–2):80–4.

22. Sallenave JM. Antimicrobial activity of antiproteinases. Biochem Soc Trans. 2002;30(2):111–5.

23. Gelperina S, Kisich K, Iseman MD, Heifets L. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1487–90.

24. Jamkhande PG, Ghule NW, Bamer AH, Kalaskar MG. Metal nanoparticles synthesis: An overview on methods of preparation, advantages and disadvantages, and applications. J Drug Deliv Sci Technol. 2019;53:101174.

25. Laurentius LB, Owens NA, Park J, Crawford AC, Porter MD. Advantages and limitations of nanoparticle labeling for early diagnosis of infection. Expert Rev Mol Diagn. 2016 Aug 2;16(8):883–95.

26. Liu Y, Welch MJ. Nanoparticles Labeled with Positron Emitting Nuclides: Advantages, Methods, and Applications. Bioconjug Chem. 2012 Apr 18;23(4):671–82.

27. Marinković NS, Adžić RR. Nanoparticle size evaluation of catalysts by EXAFS: Advantages and limitations. Zastita Mater. 2016;57(1):101–9.

28. Alavian F, Shams N. Oral and intra-nasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: considering its advantages and disadvantages. Curr Clin Pharmacol. 2020;15(1):20–9.

29. Dikmen G, Genç L, Güney G. Advantage and disadvantage in drug delivery systems. J Mater Sci Eng. 2011;5(4):468.

30. Ghasemiyeh P, Mohammadi-Samani S. Potential of Nanoparticles as Permeation Enhancers and Targeted Delivery Options for Skin: Advantages and Disadvantages. Drug Des Devel Ther. 2020 Aug;Volume 14:3271–89.

31. Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015;88(1054):20150207.

32. De M, Ghosh PS, Rotello VM. Applications of Nanoparticles in Biology. Adv Mater. 2008 Nov 18;20(22):4225–41.

33. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010;29(6):596–609.

34. Han X, Xu K, Taratula O, Farsad K. Applications of nanoparticles in biomedical imaging. Nanoscale. 2019;11(3):799–819.

35. Stark WJ, Stoessel PR, Wohlleben W, Hafner A. Industrial applications of nanoparticles. Chem Soc Rev. 2015;44(16):5793–805.

36. Singh S, Pandey VK, Tewari RP, Agarwal V. Nanoparticle based drug delivery system: advantages and applications. Indian J Sci Technol. 2011;4(3):177–80.

37. Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnology. 2004 Apr 30;2(1):3.

38. Rizvi SA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70.

39. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. J Appl Pharm Sci. 2011;(Issue):228–34.

40. Stepanauskas R, Glenn TC, Jagoe CH, Tuckfield RC, Lindell AH, King CJ, et al. Coselection for microbial resistance to metals and antibiotics in freshwater microcosms. Environ Microbiol. 2006 Sep;8(9):1510–4.

41. Scholar EM, Pratt WB. The antimicrobial drugs [Internet]. Oxford University Press; 2000 [cited 2025 Mar 21]. Available from: https://books.google.com/books?hl=en&lr=&id=ZQ6KNRLWHLQC&oi=fnd&pg=PA3&dq=Antimicrobial&ots=DmTUZh_EYJ&sig=E3mNldSQEm81JxFHf2PsaSYF1js

42. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013;65(13–14):1803–15.

43. Moore AJ, Beazley WD, Bibby MC, Devine DA. Antimicrobial activity of cecropins. J Antimicrob Chemother. 1996;37(6):1077–89.

44. Levy S. Microbial resistance to antibiotics: an evolving and persistent problem. The Lancet. 1982;320(8289):83–8.

45. Chinedum IE. Microbial resistance to antibiotics. Afr J Biotechnol [Internet]. 2005 [cited 2025 Mar 21];4(13). Available from: https://www.ajol.info/index.php/ajb/article/view/71776

46. Beam Jr TR, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis. 1992;15(Supplement_1):S5–32.

47. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin Infect Dis. 1992;15(Supplement_1):S62–88.

48. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control. 1997;25(1):51–64.

49. Gordon YJ, Romanowski EG, McDermott AM. A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs. Curr Eye Res. 2005 Jan;30(7):505–15.

50. Hanes PJ, Purvis JP. Local Anti-Infective Therapy: Pharmacological Agents. A Systematic Review. Ann Periodontol. 2003 Dec;8(1):79–98.

51. Veringa A, Sturkenboom MG, Dekkers BG, Koster RA, Roberts JA, Peloquin CA, et al. LC-MS/MS for therapeutic drug monitoring of anti-infective drugs. TrAC Trends Anal Chem. 2016;84:34–40.

52. Alberto L, Rodríguez G, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–4.

53. Glupczynski Y, Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol Springer Nat [Internet]. 1990 [cited 2025 Mar 21];85(12). Available from: https://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=00029270&AN=16121057&h=xxBeI2djB%2FjiaMXZZaO1VHG%2B%2BfTgMQPzkv0%2BIpjZMxE8yPZgGQ9%2FzlYVbEa2ssE6ALmKWJZSdQBHFnGKq7cu9A%3D%3D&crl=c

54. Kim TI, Lee YC, Lee KH, Han JH, Chon CY, Moon YM, et al. Effects of Nonsteroidal Anti-Inflammatory Drugs on *Helicobacter pylori* -Infected Gastric Mucosae of Mice: Apoptosis, Cell Proliferation, and Inflammatory Activity. Clements JD, editor. Infect Immun. 2001 Aug;69(8):5056–63.

55. Kosikowska P, Berlicki Ł. Urease inhibitors as potential drugs for gastric and urinary tract infections: a patent review. Expert Opin Ther Pat. 2011 Jun;21(6):945–57.

56. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid–suppressive drugs. Jama. 2004;292(16):1955–60.

57. Akagi T, Baba M, Akashi M. Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. In: Kunugi S, Yamaoka T, editors. Polymers in Nanomedicine [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011 [cited 2025 Mar 21]. p. 31–64. (Advances in Polymer Science; vol. 247). Available from: https://link.springer.com/10.1007/12_2011_150

58. Curley SM, Putnam D. Biological nanoparticles in vaccine development. Front Bioeng Biotechnol. 2022;10:867119.

59. Hajizade A, Ebrahimi F, Salmanian AH, Arpanaei A, Amani J. Nanoparticles in vaccine development. J Appl Biotechnol Rep. 2014;1(4):125–34.

60. Kheirollahpour M, Mehrabi M, Dounighi NM, Mohammadi M, Masoudi A. Nanoparticles and vaccine development. Pharm Nanotechnol. 2020;8(1):6–21.

61. Lozano D, Larraga V, Vallet-Regí M, Manzano M. An overview of the use of nanoparticles in vaccine development. Nanomaterials. 2023;13(12):1828.

62. Lung P, Yang J, Li Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020;12(10):5746–63.

63. Park YM, Lee SJ, Kim YS, Lee MH, Cha GS, Jung ID, et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 2013;13(5):177–83.

64. Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA. Nanoparticle Systems for Cancer Vaccine. Nanomed. 2019 Mar;14(5):627–48.

65. Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci. 2006;95(12):2738–50.

66. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–37.

67. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012;17(17–18):928–34.

68. Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919–22.

69. Ho D, Sun X, Sun S. Monodisperse Magnetic Nanoparticles for Theranostic Applications. Acc Chem Res. 2011 Oct 18;44(10):875–82.

70. Jokerst JV, Gambhir SS. Molecular Imaging with Theranostic Nanoparticles. Acc Chem Res. 2011 Oct 18;44(10):1050–60.

71. Ma X, Zhao Y, Liang XJ. Theranostic Nanoparticles Engineered for Clinic and Pharmaceutics. Acc Chem Res. 2011 Oct 18;44(10):1114–22.

72. Sharma H, Mishra PK, Talegaonkar S, Vaidya B. Metal nanoparticles: a theranostic nanotool against cancer. Drug Discov Today. 2015;20(9):1143–51.

73. Andrade F, Rafael D, Videira M, Ferreira D, Sosnik A, Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev. 2013;65(13–14):1816–27.

74. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol-Lung Cell Mol Physiol. 2008 Sep;295(3):L400–11.

75. Huang Z, Kłodzińska SN, Wan F, Nielsen HM. Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections. Drug Deliv Transl Res. 2021 Aug;11(4):1634–54.

76. Kim JS, Adamcakova-Dodd A, O'Shaughnessy PT, Grassian VH, Thorne PS. Effects of copper nanoparticle exposure on host defense in a murine pulmonary infection model. Part Fibre Toxicol. 2011 Dec;8(1):29.

77. Lim YH, Tiemann KM, Hunstad DA, Elsabahy M, Wooley KL. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. WIREs Nanomedicine Nanobiotechnology. 2016 Nov;8(6):842–71.

78. Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: a review. Int J Mol Sci. 2014;15(4):5852–73.

79. Pramanik S, Mohanto S, Manne R, Rajendran RR, Deepak A, Edapully SJ, et al. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases. Mol Pharm. 2021 Oct 4;18(10):3671–718.

80. Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J. 2009;34(3):559–67.